Bridging the gap between scientific discovery and investment-ready innovation for rare disease breakthroughs.
Developing therapies for rare diseases often requires stronger collaboration between public and private partners, including researchers, patient groups, industry and funders.
ERDERA’s Acceleration Hub is a key place where this collaboration is organised to help promising work move from early evidence towards practical development and, where appropriate, a pathway to clinical implementation. EThe ERDERA Acceleration Hub channels progress through two distinct, complementary mechanisms.
The Technology Accelerator focuses on developing and streamlining enabling therapy technologies, while the Public–Private Collaboration Accelerator (PPCA) focuses on supporting projects with development planning and connecting them to external funding and investment opportunities.
Both activities depend on effective public–private collaboration, but they serve different needs.
Technology Accelerator
Public and private partners work together to advance enabling ATMP delivery technologies and platforms (including AAV‑derived vectors, mRNA and lipid nanoparticles), addressing aspects such as manufacturing, analytical characterisation and immunogenicity to build a robust toolbox for the rare disease community.
Public–Private Collaboration Accelerator (PPCA)
An open innovation marketplace where researchers can propose projects and connect with R&D experts, patient groups and public and private funders and investors, with support to become ready for external funding resources and to identify a viable route to implementation.
By bringing these two accelerators together under one hub, ERDERA strengthens public–private collaboration in two ways: by maturing enabling technologies and by supporting projects to build credible development plans and access the right expertise and funding to move forward.
You might also be interested in
